JP7846132B2 - Nav1.8阻害薬としてのアリール 3-オキソピペラジンカルボキサミド類及びヘテロアリール 3-オキソピペラジンカルボキサミド類 - Google Patents

Nav1.8阻害薬としてのアリール 3-オキソピペラジンカルボキサミド類及びヘテロアリール 3-オキソピペラジンカルボキサミド類

Info

Publication number
JP7846132B2
JP7846132B2 JP2023567930A JP2023567930A JP7846132B2 JP 7846132 B2 JP7846132 B2 JP 7846132B2 JP 2023567930 A JP2023567930 A JP 2023567930A JP 2023567930 A JP2023567930 A JP 2023567930A JP 7846132 B2 JP7846132 B2 JP 7846132B2
Authority
JP
Japan
Prior art keywords
methyl
oxopiperazine
carboxamide
chloro
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023567930A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024519487A (ja
JP2024519487A5 (https=
JPWO2022235558A5 (https=
Inventor
アラサッパン,アショク
ベル,イアン・エム
コックス,ジェイソン・エム
ケリー,マイケル・ジェイ・ザ・サード
レイトン,マーク・エリック
リウ,ホン
リウ,ジャン
シャー,アクシェイ・エー
ヴァンヘイスト,マイケル・ディー
Original Assignee
メルク・シャープ・アンド・ドーム・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メルク・シャープ・アンド・ドーム・エルエルシー filed Critical メルク・シャープ・アンド・ドーム・エルエルシー
Publication of JP2024519487A publication Critical patent/JP2024519487A/ja
Publication of JP2024519487A5 publication Critical patent/JP2024519487A5/ja
Publication of JPWO2022235558A5 publication Critical patent/JPWO2022235558A5/ja
Application granted granted Critical
Publication of JP7846132B2 publication Critical patent/JP7846132B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2023567930A 2021-05-07 2022-05-02 Nav1.8阻害薬としてのアリール 3-オキソピペラジンカルボキサミド類及びヘテロアリール 3-オキソピペラジンカルボキサミド類 Active JP7846132B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163185608P 2021-05-07 2021-05-07
US63/185,608 2021-05-07
PCT/US2022/027262 WO2022235558A1 (en) 2021-05-07 2022-05-02 Aryl 3-oxopiperazine carboxamides and heteroaryl 3-oxopiperazine carboxamides as nav1.8 inhibitors

Publications (4)

Publication Number Publication Date
JP2024519487A JP2024519487A (ja) 2024-05-14
JP2024519487A5 JP2024519487A5 (https=) 2024-06-05
JPWO2022235558A5 JPWO2022235558A5 (https=) 2024-06-05
JP7846132B2 true JP7846132B2 (ja) 2026-04-14

Family

ID=83932809

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023567930A Active JP7846132B2 (ja) 2021-05-07 2022-05-02 Nav1.8阻害薬としてのアリール 3-オキソピペラジンカルボキサミド類及びヘテロアリール 3-オキソピペラジンカルボキサミド類

Country Status (10)

Country Link
US (1) US20240246932A1 (https=)
EP (1) EP4334306A4 (https=)
JP (1) JP7846132B2 (https=)
KR (1) KR20240006606A (https=)
CN (1) CN117597339A (https=)
AU (1) AU2022270061B2 (https=)
BR (1) BR112023023186A2 (https=)
CA (1) CA3217605A1 (https=)
MX (1) MX2023013147A (https=)
WO (1) WO2022235558A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025513452A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
UY40234A (es) 2022-04-22 2023-11-15 Vertex Pharma Compuestos heteroarilo para el tratamiento del dolor
GEAP202516634A (en) 2022-04-22 2025-02-25 Vertex Pharma Heteroaryl compounds for the treatment of pain
AU2023257313A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
AU2023391870A1 (en) 2022-12-06 2025-06-05 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
WO2025090511A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing modulators of sodium channels and solid forms of the same for treating pain
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090465A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
WO2025122953A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain
US20260001877A1 (en) 2024-06-28 2026-01-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2026013449A2 (en) 2024-07-11 2026-01-15 Sea4Us - Biotecnologia E Recursos Marinhos, Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain
WO2026030525A1 (en) 2024-07-31 2026-02-05 Vertex Pharmaceuticals Incorporated Zilvetrigine dosage forms and dosing regimens for treating pain

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011026240A1 (en) 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Oxopiperazine derivatives for the treatment of pain and epilepsy
JP2023524167A (ja) 2020-06-17 2023-06-08 メルク・シャープ・アンド・ドーム・エルエルシー Nav1.8阻害剤としての2-オキソイミダゾリジン-4-カルボキサミド
JP2023530320A (ja) 2020-06-17 2023-07-14 メルク・シャープ・アンド・ドーム・エルエルシー Nav1.8阻害剤としての5-オキソピロリジン-3-カルボキサミド
JP2023530319A (ja) 2020-06-17 2023-07-14 メルク・シャープ・アンド・ドーム・エルエルシー Nav1.8阻害剤としての2-オキソ-オキサゾリジン-5-カルボキサミド
JP2024515895A (ja) 2021-05-07 2024-04-10 メルク・シャープ・アンド・ドーム・エルエルシー Nav1.8阻害薬としてのシクロアルキル 3-オキソピペラジンカルボキサミド類及びシクロヘテロアルキル 3-オキソピペラジンカルボキサミド類

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007002410A (es) * 2004-08-30 2007-05-07 Neuromed Pharmaceuticals Ltd Derivados de urea como bloqueadores de canal de calcio.
US7767680B2 (en) * 2004-11-03 2010-08-03 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
JP5361857B2 (ja) * 2007-03-23 2013-12-04 ファイザー・リミテッド イオンチャネルの阻害剤
EP3873893A1 (en) * 2018-11-02 2021-09-08 Merck Sharp & Dohme Corp. 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011026240A1 (en) 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Oxopiperazine derivatives for the treatment of pain and epilepsy
JP2023524167A (ja) 2020-06-17 2023-06-08 メルク・シャープ・アンド・ドーム・エルエルシー Nav1.8阻害剤としての2-オキソイミダゾリジン-4-カルボキサミド
JP2023530320A (ja) 2020-06-17 2023-07-14 メルク・シャープ・アンド・ドーム・エルエルシー Nav1.8阻害剤としての5-オキソピロリジン-3-カルボキサミド
JP2023530319A (ja) 2020-06-17 2023-07-14 メルク・シャープ・アンド・ドーム・エルエルシー Nav1.8阻害剤としての2-オキソ-オキサゾリジン-5-カルボキサミド
JP2024515895A (ja) 2021-05-07 2024-04-10 メルク・シャープ・アンド・ドーム・エルエルシー Nav1.8阻害薬としてのシクロアルキル 3-オキソピペラジンカルボキサミド類及びシクロヘテロアルキル 3-オキソピペラジンカルボキサミド類

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REGISTRY (STN) [online],2013.04.11[検索日 2025.03.14] CAS登録番号 1427971-52-5 他、全18化合物

Also Published As

Publication number Publication date
JP2024519487A (ja) 2024-05-14
AU2022270061B2 (en) 2026-02-19
MX2023013147A (es) 2023-11-28
BR112023023186A2 (pt) 2024-01-30
AU2022270061A1 (en) 2023-11-16
KR20240006606A (ko) 2024-01-15
EP4334306A4 (en) 2025-04-02
US20240246932A1 (en) 2024-07-25
EP4334306A1 (en) 2024-03-13
CN117597339A (zh) 2024-02-23
WO2022235558A1 (en) 2022-11-10
CA3217605A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
JP7846132B2 (ja) Nav1.8阻害薬としてのアリール 3-オキソピペラジンカルボキサミド類及びヘテロアリール 3-オキソピペラジンカルボキサミド類
JP7575518B2 (ja) Nav1.8阻害剤としての2-オキソイミダゾリジン-4-カルボキサミド
US12516046B2 (en) 2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors
TWI827037B (zh) 作為nav1.8抑制劑之環烷基3-側氧基哌甲醯胺及環雜烷基3-側氧基哌甲醯胺
KR20230026405A (ko) Nav1.8 억제제로서의 5-옥소피롤리딘-3-카르복스아미드
CA3182610C (en) 2-oxo-oxazolidine-5-carboxamides as nav1.8 inhibitors
EA048797B1 (ru) 2-оксоимидазолидин-5-карбоксамиды в качестве ингибиторов nav1.8

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240528

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240528

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250804

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251203

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260310

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260402

R150 Certificate of patent or registration of utility model

Ref document number: 7846132

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150